<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03145558</url>
  </required_header>
  <id_info>
    <org_study_id>LT-006</org_study_id>
    <nct_id>NCT03145558</nct_id>
  </id_info>
  <brief_title>TATE Versus TACE in Intermediate Stage HCC</brief_title>
  <acronym>TATE</acronym>
  <official_title>TATE Versus TACE, an Open-label Randomized Study Comparing TransArterial Tirapazamine Embolization Versus TransArterial ChemoEmbolization in Intermediate Stage Hepatocellular Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Teclison Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Teclison Ltd.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      An open label randomized study to compare TATE versus TACE in patients with intermediate&#xD;
      stage Hepatocellular carcinoma who are not suitable for surgical resection or radiofrequency&#xD;
      ablation. The primary endpoint is Progression Free Survival. Secondary endpoints including CR&#xD;
      rate, Time to embolization failure, Duration of CR, OS, ORR, local control rate, time to&#xD;
      local recurrence and duration to local recurrence. The study treatment is to compare&#xD;
      Tirapazamine versus doxorubicin when combined with trans-arterial embolization. Study plans&#xD;
      to enroll 134 patients in 1:1 randomization for TATE or TACE. MRI will be used to assess&#xD;
      efficacy using a central radiological review for the final analysis.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Trans-arterial chemoembolization (TACE) is a standard care of intermediate stage&#xD;
      Hepatocellular carcinoma (HCC) for 40 years without much improvement in efficacy. The key&#xD;
      reason for lack of progress is that chemotherapy agents are not effective in hypoxia and&#xD;
      cancer stem cells are induced under hypoxia. Tirapazamine, a hypoxia activated agent, can&#xD;
      potential solve these two problems. This open label randomized trial will be conducted in HCC&#xD;
      patients who are in intermediate stage and naive to embolization, Child Pugh up to B7 and&#xD;
      with normal organ functions. Patients will be randomized 1:1 to receive TATE (trans-arterial&#xD;
      tirapazamine embolization) or conventional TACE. The goal of treatment aims to achieve CR by&#xD;
      mRECIST for every patient. If there is evidence of viable lesion, patients should be treated&#xD;
      again. All patients are followed by contrast MRI scans every 2 months in the first year and&#xD;
      every 3 months afterwards until patients have evidence of progression and no longer&#xD;
      considered suitable for TATE/TACE. Survival will be followed for 3 years. Total sample size&#xD;
      will be 134 patients with the total study duration for 3 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">December 5, 2017</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>1:1 randomization, open label with central radiological review</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
    <masking_description>Central radiology reviewers are blinded.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Progression Free Survival</measure>
    <time_frame>within 2 years</time_frame>
    <description>mRECIST criteria</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>3 years</time_frame>
    <description>From randomization to death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complete Response rate</measure>
    <time_frame>2 years</time_frame>
    <description>CR rate based on mRECIST criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Embolization Failure</measure>
    <time_frame>1 year</time_frame>
    <description>From randomization to stage progression</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of CR</measure>
    <time_frame>1 year</time_frame>
    <description>From randomization to recurrence in those patients who achieved CR</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Local recurrence rate</measure>
    <time_frame>1 year</time_frame>
    <description>Recurrence rate in the embolized lesion</description>
  </other_outcome>
  <other_outcome>
    <measure>Time to local recurrence</measure>
    <time_frame>2 years</time_frame>
    <description>From randomization to local recurrence</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">134</enrollment>
  <condition>Carcinoma, Hepatocellular</condition>
  <arm_group>
    <arm_group_label>Trans-Arterial Tirapazamine Embolization (TATE)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will receive a fixed dose of Tirapazamine combined with embolization using Lipiodol and Gelfoam.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Trans-Arterial ChemoEmbolization (TACE)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients will receive a mixture of doxorubicin and Lipiodol into the tumor feeding artery followed by injection of Gelfoam to induce embolization per standard procedure.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tirapazamine</intervention_name>
    <description>Replacing the standard chemotherapy agent doxorubicin used in TACE with tirapazamine</description>
    <arm_group_label>Trans-Arterial Tirapazamine Embolization (TATE)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Doxorubicin</intervention_name>
    <description>Standard of care for TACE</description>
    <arm_group_label>Trans-Arterial ChemoEmbolization (TACE)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        1. Confirmed diagnosis of HCC by imaging criteria per American Association for the Study&#xD;
             of Liver Diseases (AASLD) criteria.&#xD;
&#xD;
          2. Patients with single or multiple HCC who are unsuitable for surgical resection or RFA,&#xD;
             but suitable for embolization.&#xD;
&#xD;
          3. ECOG score 0-1. Child-Pugh score up to B7.&#xD;
&#xD;
          4. Patients should have measurable tumor lesion(s) by contrast MRI.&#xD;
&#xD;
          5. Patients have adequate normal organ function and suitable laboratory criteria.&#xD;
&#xD;
          6. Men and women of child-bearing age need to commit to using two levels of contraception&#xD;
             simultaneously to avoid pregnancy.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients who have had a liver transplantation.&#xD;
&#xD;
          2. Patients who have uncontrolled major medical problems such as cardiac, pulmonary (COPD&#xD;
             requiring constant oxygen), renal (creatinine over 2.0) diseases, active infectious&#xD;
             diseases (except chronic Hepatitis B or C), or non-healing ulceration.&#xD;
&#xD;
          3. Patients who have any clinical evidence of hypoxia with O2 saturation less than 92% on&#xD;
             room air.&#xD;
&#xD;
          4. Patients with evidence of arterial insufficiency or microangiopathy in any organ due&#xD;
             to any reason, which could lead to distal extremity hypoxia, as evidenced by any&#xD;
             gangrenous change in distal limbs or requiring resection for this reason.&#xD;
&#xD;
          5. Patients with poorly controlled HBV infection.&#xD;
&#xD;
          6. Patients on interferon treatment need to have at least 2-week washout period from Day&#xD;
             1.&#xD;
&#xD;
          7. Patients with major gastrointestinal bleeding in the prior 2 months of enrollment or&#xD;
             known diagnosis of cancer other than HCC.&#xD;
&#xD;
          8. Pregnant or lactating women.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nadine Abi-Jaoudeh, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, Irvine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of California, Irvine</name>
      <address>
        <city>Irvine</city>
        <state>California</state>
        <zip>92868</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oregon Health Science University</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical College of Wisconsin</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53226</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>May 3, 2017</study_first_submitted>
  <study_first_submitted_qc>May 4, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">May 9, 2017</study_first_posted>
  <last_update_submitted>January 6, 2021</last_update_submitted>
  <last_update_submitted_qc>January 6, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 7, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Tirapazamine, embolization, TACE, Hepatocellular carcinoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Tirapazamine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

